First-line chemotherapy with fluorouracil-epirubicin-navelbine (FEN) combination in advanced breast cancer

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4493-4498

  Ardavanis, A ^a   Tryfonopoulos, D ^a   Orphanos, G ^a   Ioannidis, G ^a   Karamouzis, M ^a   Rigatos, G ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

5 Fluorouracil; Breast cancer; Epirubicin; Vinorelbine

Indexed keywords

EPIRUBICIN; FLUOROURACIL; NAVELBINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN MANIFESTATION; STOMACH DISEASE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; VINBLASTINE;

EID: 28444462791     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Negri E, La Vecchia C and Decarli A: Cancer mortality in Italy, 1997: quantifying the fall in rates in women and men. Tumori 87(5): 290-298, 2001.
2. Parkin DM, Pisani P and Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80(6): 827-841, 1999.
3. Peto R, Boreham J, Clarke M, Davies C and Beral V: UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355(9217): 1822, 2000.
4. Jemal A, Thomas A, Murray T and Thun M: Cancer statistics, 2002. CA Cancer J Clin 52(1): 23-47, 2002.
5. Fornier M, Munster P and Seidman AD: Update on the management of advanced breast cancer. Oncology 13(5): 647-658, 1999.
6. Fellous A, Ohayon R, Vacassin T, Binet S, Lataste H, Krikorian A, Couzinier JP and Meininger V: Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 16(2 Suppl 4): 9-14, 1989.
7. Gregory RK and Smith IE: Vinorelbine - a clinical review. Br J Cancer 82(12): 1907-1913, 2000.
8. Budman DR: Vinorelbine (Navelbine): a third-generation vinca alkaloid. Cancer Invest 75(5): 475-490, 1997.
9. Romero A, Rabinovich MG, Vallejo CT, Ferez JE, Rodriguez R, Cuevas MA, Machiavelli M, Lacava JA, Langhi M, Romero Acuna L et al: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12(2): 336-341, 1994.
10. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB and Ambrosini G: Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 12(10): 2094-2101, 1994.
11. Spielmann M, Dorval T, Turpin F, Antoine E, Jouve M, Maylevin F, Lacombe D, Rouesse J, Pouillart P, Tursz T et al: Phase II trial of vinorelbine/ doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12(9): 1764-1770, 1994.
12. Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss P, Latreille J, Rudinskas L, Lofters W, Trudeau M, Osoba D and Rodgers A: Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MAS. J Clin Oncol 18(72): 2385-2394, 2000.
13. Blomqvist C, Hietanen P, Teerenhovi L and Rissanen P: Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study. Eur J Cancer 31A(13-14): 2406-2408, 1995.
14. Pawlicki M, Rolski J, Zaluski J, Siedlecki P, Ramlau C and Tomzak P: A phase II study of intravenous navelbine and doxorubicin combination in previously untreated advanced breast carcinoma. Oncologist 7(3): 205-209, 2002.
15. Vici P, Colucci G, Gebbia V, Amodio A, Giotta F, Belli F, Conti F, Gebbia N, Pezzella G, Valeric MR, Brandi M, Pisconti S, Durini E, Giannarelli D and Lopez M: First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. J Clin Oncol 20(77): 2689-2694, 2002.
16. Dieras V, Extra JM, Bellissant E, Espie M, Morvan F, Pierga JY, Mignot L, Tresca P and Marry M: Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 14(12): 3097-3104, 1996.
17. Zambetti M, Demicheli R, De Candis D, Antonelli G, Giacobone A, Terenziani M, Laffranchi A, Garbagnati F, Biasi S and Bonadonna G: Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients. Breast Cancer Res Treat 44(3): 255-260, 1997.
18. Nole F, de Braud F, Aapro M, Minchella I, De Pas M, Zampino MG, Monti S, Andreoni G and Goldhirsch A: Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. Ann Oncol 8(9): 865-870, 1997.
19. Kornek GV, Haider K, Kwasny W, Lang F, Krauss G, Hejna M, Raderer M, Weinlander G, Depisch D and Scheithauer W: Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and 1-leucovorin plus human granulocyte colony-stimulating factor. Br J Cancer 78(5): 673-678, 1998.
20. Ardavanis A, Extra JM, Espie M, Cuvier C and Marry M: Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer. In Vivo 72(5): 559-562, 1998.
21. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
22. Guler N, Yucel I, Ozet A et al: Vinorelbine, epirubicin and 5-fluorouracil combination in the first-line treatment of metastatic breast carcinoma (TOG-009 protocol). Ann Oncol 11(Suppl 4):33, 2000.
23. Elomaa I, Joensuu H and Blomqvist C: Vinorelbine, epirubicin and fluorouracil as first-line therapy in metastatic breast cancer - a phase II trial. Acta Oncol 42(4): 309-314, 2003.
24. Berruti A, Bitossi R, Bottini A, Bonardi S, Donadio M, Nigro C, Bertetto O, Danese S, Bertone E, Sarobba MG, Farris A, Katsaros D, Castiglione F, Volpe T, Lattuada S, Mancarella S and Dogliotti L: Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients. Eur J Cancer 41(2): 249-255, 2005.